Home   About the Journal  Editorial Board  Online Journal   Publishing Ethics   Contact Us  Chinese Version
You are here:Home => Online Journal => Vol.36 No.11 => Reviews =>
Drug resistance of direct-acting antivirals in genotype 2/3 hepatitis C virus
文章发布日期:2020年10月22日  来源:  作者:陈宏宇,徐小元  点击次数:145次  下载次数:43次
Adjust font size:Small regular big

【Abstract】:Since the development of direct-acting antivirals (DAAs) for hepatitis C virus(HCV), more than 95% of the patients with hepatitis C can be cured, but a very small proportion of patients still face treatment failure. There are many reasons for treatment failure, among which HCV genotype and resistance-associated substitutions (RASs) in virus genes show a certain impact. This article mainly introduces the RASs associated with the NS5B and NS5A gene fragments in genotype 2/3 HCV, summarizes the distribution of RASs, and compares the difference in the distribution of RASs between previously untreated chronic hepatitis C patients and patients with treatment failure.
【Key words】:hepacivirus; antiviral agents; therapeutics

Mail address: Editorial Office of Journal of Clinical Hepatology, 519 Dongminzhu Street, Changchun, Jilin, China Postal code: 130061 Tel:+86-431-88782542/3542
Journal of Clinical Hepatology Copyright © 2009 - 2013 Lcgdbzz.org. All Rights Reserv 吉ICP备10000617号